Pharmacogenetics and Genomics

Papers
(The median citation count of Pharmacogenetics and Genomics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target15
Establishing national reference materials for genetic testing of cytochrome P45014
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients11
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation11
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the10
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation9
Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis9
The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia9
Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort9
The impact of genetic variations in FPGS, MTHFR, and ATIC on methotrexate response among pediatric patients with acute lymphoblastic leukemia8
Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines7
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) June 12-13, 2023 Memphis, TN, USA7
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort7
PharmGKB summary: disulfiram pathway6
Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy6
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy6
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics6
Genome-wide DNA methylation profile of peripheral blood lymphocytes from subjects with nonsteroidal anti-inflammatory drug-induced respiratory diseases5
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis5
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer5
Mouse nerve growth factor suppresses neuronal apoptosis in valproic acid-induced autism spectrum disorder rats by regulating the phosphoinositide-3-kinase/serine/threonine kinase signaling pathway4
Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation4
Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy4
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs4
Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis4
HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation4
Pharmacogenomic allele coverage of genome-wide genotyping arrays: a comparative analysis4
Updated analysis of the pharmacogenomics of pediatric bronchodilator response3
Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension3
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care3
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens3
Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects3
Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease3
Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia3
Identification of potential druggable targets of cell cycle with small-molecule inhibitors in oral squamous cell carcinoma3
Associations of ADH1B and ALDH2 genotypes and alcohol flushing with drinking history, withdrawal symptoms, and ICD-10 criteria in Japanese alcohol-dependent men2
Effect of CYP3A4*22, CYP3A5*3 and POR*28 genetic polymorphisms on calcineurin inhibitors dose requirements in early phase renal transplant patients2
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients2
Metabolic effects of heterocyclic amines on insulin‑induced AKT phosphorylation and gluconeogenic gene expression are modified by N-acetyltransferase 2 genetic polymorphism2
Diversity of oncopharmacogenetic profile within Spanish population2
MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway2
Association of ATP8B3 gene polymorphisms with aspirin-exacerbated respiratory disease in asthmatics2
Pan-cancer single-cell landscape of drug-metabolizing enzyme genes2
Microsampling with dried blood spots and mass spectrometry enables PK/PD profiling of responses to praziquantel in a Schistosoma haematobium–exposed Zimbabwean population2
Cytochrome P4503A4 gene polymorphisms guide safe sufentanil analgesic doses in pregnant Chinese mothers: a multicenter, randomized, prospective study2
Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network2
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis2
PharmGKB summary: acyclovir/ganciclovir pathway2
The c.415C>T polymorphism in NUDT15 is more frequent than the polymorphisms in TPMT in Chilean patients who use thiopurine drugs2
Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients1
‘Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation’ by Ali et al.1
Evaluation of tagged SNPs for HLA markers, HLA-B*15:02 and HLA-A*31:01, that are used to predict carbamazepine induced adverse effects: Erratum1
Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype1
Attitudes on pharmacogenomic results as secondary findings among medical geneticists1
Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity1
Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature1
Prevalence of CYP2D6 structural variation in large retrospective study1
Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen1
Pharmacogenetics at scale in real-world bioresources: CYP2C19 and clopidogrel outcomes in UK Biobank1
Bone marrow mesenchymal stem cell-derived exosomes carrying E3 ubiquitin ligase ITCH attenuated cardiomyocyte apoptosis by mediating apoptosis signal-regulated kinase-11
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV1
Implementation of pharmacogenomics into inpatient general medicine1
Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants1
Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes1
Cisplatin-induced ototoxicity: a novel approach to an ancient problem1
Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy1
Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents1
Annual Scientific Meeting of the Pharmacogenomics Global Research Network (PGRN) September 23-25, 2024 at the Ohio State University in Columbus, Ohio, USA1
Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated?1
Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes1
Association between opioid and dopamine receptor gene polymorphisms OPRM1rs1799971, DAT VNTR9-10 repeat allele, DRD1 rs4532 and DRD2 rs1799732 and alcohol dependence: an ethnicity oriented meta-analys1
Incorporating G6PD genotyping to identify patients with G6PD deficiency1
Association of the ACE and AGT gene polymorphisms with global disparities in COVID-19-related deaths1
0.042588949203491